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Legislative incentives enacted in Europe through the Regulation (EC) No. 141/2000 to incentivize orphan drug
development have over the last 12 years constituted a powerful impetus toward R&D directed at the rare diseases
population.
However, despite therapeutic promises contained in these projects and significant economic impact linked to
burgeoning R&D expenditures, the affordability and value of OMPs has become a topic of health policy debate in
Europe fueled by the perception that OMPs have high acquisition costs, and by misconceptions around pricing
dynamics and rare-diseases business models. In order to maintain sustainable patient access to new and innovative
therapies, it is essential to address these misconceptions, and to ensure the successful continuation of a dynamic
OMPs R&D within rare-diseases public health policy.
Misconceptions abound regarding the pricing of rare diseases drugs and reflect a poor appreciation of the R&D
model and the affordability and value of OMPs.
Simulation of potential financial returns of small medium sized rare diseases companies focusing on high priced
drugs show that their economic returns are likely to be close to their cost of capital. Research in rare diseases is a
challenging endeavour characterised by high fixed costs in which companies accrue substantial costs for several
years before potentially generating returns from the fruits of their investments. Although heavily dependent upon
R&D capabilities of each individual company or R&D organization, continuous flow of R&D financial investment
should allow industry to increasingly include efficiencies in research and development in cost considerations to its
customers. Industry should also pro-actively work on facilitating development of a specific value based pricing
approach to help understanding what constitute value in rare diseases. Policy makers must reward innovation
based upon unmet need and patient outcome. Broader understanding by clinicians, the public, and policy makers
of the complexity of clinical programs to deliver OMPs to market is required to better comprehend the decisions
needed and made by industry. In parallel, an overt effort to consider the impact of public policies on R&D
investments is key to enable policy makers to better reconcile the incentives provided by public policy decisions
and companies investments decisions in a more positive manner.Introduction
Orphan Medicinal Products (OMPs) are intended for
the diagnosis, prevention or treatment of serious, rare
diseases that substantially affect life expectancy, physical
and social functioning of patients and their families
[1-4]. Since the introduction of EU OMP regulation in
the year 2000, there has been a powerful impetus for
research and development (R&D) in the rare diseases
field and there are now more than 1,000 medicines with
OMP designation. As a result, OMP R&D expenditures* Correspondence: pierrick.rollet@gsk.com
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reproduction in any medium, provided the orin the EU have more than tripled between 2000 and
2008 and overall employment in all departments of
companies working on OMPs have more than doubled
between 2000 and 2008 driven by increasing number
of R&D activities and staff located in the EU [5]. The
dramatic increase in OMP designations shows a desire
to advance scientific understanding of disease mechanisms
and a willingness to seek new drugs that offer therapeutic
benefit to patients and families for whom no effective
treatment options are available.
However, despite the promises offered by this surge in
orphan designations and corresponding R&D expenditures,
the affordability and value of OMPs has become a topic oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that OMPs have high acquisition costs and by questions-
misconceptions around pricing dynamics and rare diseases
business models. These commonly encountered miscon-
ceptions are:
1. OMPs are high priced and are significantly more
expensive than non orphan drugs
2. Budget impact of OMPs is high and high priced
OMPs exacerbates affordability problem for health
care budgets
3. Factors affecting R&D investments and returns are
more favorable for OMPs
4. Cost of Manufacturing should determine the fair
price of OMPs
5. Rare diseases companies are making excessive
financial returns thanks to high priced drugs
In order to maintain sustainable patient access to
new and innovative therapies, it is essential to address
these misconceptions, and to ensure the successful con-
tinuation of dynamic OMPs R&D within rare-diseases
public health policy. Failure to do so will result in an
“innovation pile-up”, such that patients with rare dis-
eases in Europe will not be able to access the benefits
afforded by scientific innovation. Previous authors have
contributed to address some of the common questions
related to orphan drug development and its regulation
[7]. This article aims at providing a complementary
industry perspective on some of the key questions and
misconceptions related to value-pricing and the business200 735 € 
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OMPs are high priced and are significantly more
expensive than non-orphan drugs?
A common perception is that many rare-disease drugs
are high priced and offer higher prices than non orphan
drugs [8]. Using public list prices [9] and approved EMA
dosing schedule [10], a thorough comparative analysis of
annual weighted treatment costs of all OMPs approved
in Europe as of December 2012, shows a more complex
picture.
First, a review of the profile of all 89 OMPs approved
in EU between 2000 and 2012 reveals that rare diseases
treatments offer is not uniform but can be regrouped
along 4 homogeneous categories.
Orphan oncology drugs do represent a first category
and the majority of approved OMPs in Europe (44%-
Figure 1 below). These treatments often indicated across
multiple cancer indications present, in their majority,
efficacy data across consistent clinical end points such
as overall survival or progression free survival. Such
homogeneous data set facilitates comparative value defin-
ition and pricing comparison across oncology treatments.
A second category includes repurposed drugs which,
by definition, originate from an extended development
in a rare disease indication of an established product
approved for a common disease indication. They only
represent 10% of approved OMPs in EU and from a pri-
cing perspective, the initial common disease indication
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the approved OMPs in EU and which share with the
latter group the feature of available price comparator
against which to position value and price of a new
treatment.
A last category covers first to market, non oncology
OMPs. These drugs represent 30% of the approved
OMPs in EU and are characterized by no approved
treatments as standard of care at time of approval. In
their majority, they target chronic, degenerative, very
rare diseases (average population size of 5 000 patients
across main five EU countries). These drugs are also rep-
resentative of heterogonous clinical circumstances. Data
packages are diverse with end points supporting efficacy
of these treatments neither consistent nor comparable
across drugs. As a result, they are the category of rare
diseases treatments where pricing and reimbursement
decisions are often the hardest to define and justify.
We conducted a comparison of the mean price of the
above described OMPs categories versus annual treat-
ment cost of a sample of non-rare diseases hospital
specialty drugs across the top 5 European countries
(France, Germany, Italy, Spain, UK). List of drugs is
described in detail in the online Technical Additional
file 1.
Our comparative pricing analysis shows that price
points (yearly patient costs per course) for first-to-mar-
ket non-oncology rare disease treatments are in the
high range with the average price per patient per year
of 200,000 Euros. In contrast, non-oncology repurposed
and second-to-market OMPs are characterized by price
points in the range of 16,000 – 24,000 Euros per patient
which compares to mean yearly treatment costs of 13.000
Euros for Rheumatoid Arthritis non orphan hospital
drugs approved in EU. The average cost per cycle for
oncology OMPs is in the range of 35,000 Euros per patient
and similar to non-orphan oncology drugs (Figure 1
below).
The methodologies used for above analysis deserve a
few comments. First, the geographic scope of our ana-
lysis is most populated EU 5 countries which present
homogeneous economic purchasing power [11], hence
a relevant base for pricing comparison and analysis.
Second, the presented average price of EU approved
second to market OMPs exclude one drug “velaglucerase-
alfa”. The rationale is that although “velaglucerase-alfa”
is on average priced at a 4% discount (list price) across
EU 5 countries versus the reference treatment “Imiglu-
cerase” for a patient of similar weight in the same
disease indication, “velaglucerase-alfa” represent, from
price point perspective, a clear outlier against other
approved 2nd to market OMPs. If including “vela-
glucerase-alfa” in the analysis, the average price of 2nd to
market OMPs approved across most populated EU 5countries would increase to 56–000 Euros per patient
per year.
Third, rheumatoid arthritis treatments are a very
relevant non rare diseases category against which to
benchmark prices of non oncology rare diseases drugs
because of their very similar profile and delivery setting
in comparison to OMPs. They are hospital drugs pre-
scribed and delivered in a similar high specialized hos-
pital setting. Similar to majority of rare diseases drugs,
they also target chronic degenerative diseases and often
“compete” at hospital level with budget of rare diseases
drugs [12]. In addition, approved across multiple indi-
cations (in majority non orphan) but indicated in USA
with orphan status in only a few indications such as
paediatric ideopathic RA (Adalimumab), some authors
are using above $1 billion sales level generated by these
RA drugs across all indications to present and position
them as “orphan sales blockbusters” and main OMPs
driving potential affordability challenges [13,14]. For all
these reasons, a pricing comparison between these drugs
and rare diseases treatments is therefore relevant. For
non-orphan oncology drugs, the selected comparison
base is oncology treatments which, across their multiple
indications, represent the majority part (2/3) of oncology
volume of prescriptions in Europe [10].
In conclusion, against all common perceptions, OMP
prices are clearly differentiated along rare-diseases pro-
duct-categories. The majority of approved Orphan drugs
(70%) have lower prices or in the range of other non-rare
diseases specialty hospital drugs. Only 30% of all approved
OMPS in EU have much higher prices.
Budget impact of OMPs is high and high priced
OMPs exacerbates affordability problem for
health care budgets?
A commonly encountered comment is that rare diseases
drugs have high budget impact and that that OMPs
with high prices described in previous chapter would
constitute a substantial affordability challenge to healthcare
budgets.
Current context of economic crisis in Europe clearly
obligates and justifies the need to pay close attention to
drugs budget impact since a substantial part of these
costs are financed by national healthcare insurance
systems. For rare diseases drugs, their budget impact in
Europe is in fact low, in the range of 1% -4.6% of total
drug spending [15-17]. OMPs with the highest price
levels are also those that turn out to have the smallest
budget impact. This is confirmed by an analysis from
France, the country in Europe with the largest number
of reimbursed OMPs, where orphan oncology drugs
were accounting for more than 60% of total orphan
drug spending in 2010 and they were also the drugs
with the lowest price points among all OMPs [16]. The
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drug price influences the budget impact of rare diseases
treatments and drives affordability.
Importantly, the budget impact of OMPs is concen-
trated in a very small number of drugs. France again
serves as a good case study. A recent AFM (*) report
showed that five drugs accounted for about 50% of the
French OMP budget impact in 2010 [16]. In terms of
future dynamics, recent research indicates that the
budget impact of OMPs in the EU is likely to plateau in
next 5 years, to a level of 4%-6% of total drug spending,
with this plateau effect driven by patent-losses among
the very few drugs that contribute the most to the
budget impact [15].
Increasing economic constraints in Europe make policy
makers and healthcare managers concerned that budget
impact of OMPs is prohibitive and that OMPs with high
prices could constitute a substantial affordability challenge
to healthcare budgets [18]. Such concerns are legitimate
and it is key that the rationale and appropriate use of
OMPs balance the interests of all stakeholders amid the
growing cost pressures and uncertainties that permeate
implementation of a given drug post launch.
Against these concerns, publicly available national
statistics show however that OMP budget impact is low
due to small population size and will likely plateau in
next 5 years. Budget impact is also concentrated in a
small number of drugs, mostly oncology treatments
with prices no different to non orphan cancer products.
OMPs with the highest price levels are in addition
those that turn out to have the smallest budget impact.
The concerns that OMPs with high prices and their
budget impact poses a substantial affordability budget
challenge to healthcare systems do not therefore appear
to be justified.
In this evolving environment, new models for handling
uncertainty and ensuring value continue to be developedFigure 2 Schematic view of investment and return periods for the dewith a growing interest among payers for agreements
that involve country-specific innovative performance-
based or “risk-sharing” elements [19,20]. This means
that to overcome potential tension between funding of
OMPs and affordability, concentration of budget impact
in a few rare diseases drugs makes potentially any sig-
nificant affordability issue more easily “localized” while
providing potential incentive to develop mechanisms
that can help control costs without negatively impacting
their patient populations.
(*) Association Française contre les Myopathies.
Factors affecting R&D investments and returns
are more favorable for OMPs?
Following US Orphan Drug Act (ODA) introduced in
1983, a significant number of countries in Europe and
Australasia have established OMP regulatory pathways.
These specific legislative incentives have created favorable
environment to invest in R&D programs for OMPs. This
has materialized for example in a significant increase in
number of OMP designation approved in EU & USA
[21]. Arguing of these specific legislative incentives, some
authors have commented that factors affecting R&D
investments and returns are more favorable for OMPs
[22,23].
In reality, these perceptions overlook a number of
structural factors at play that affect pharmaceutical R&D
investments across diseases, including in rare diseases.
A dynamic analysis of main constituents that influence
R&D programs and economic returns for a new medicine
offers a more contrasted perspective.
First, the development cycle of any drug, including
OMPs, obeys the same structural features of a lengthy
process in which industry accrues substantial costs for
several years before potentially generating revenues and
returns from the fruits of R&D (See Figure 2 below).
Time-value of money, together with other costs impactingvelopment of pharmaceuticals.
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therefore a key constituent of R&D returns of any drugs,
including OMPs.
Second, four drivers - success rates, development times,
R&D out-of-pocket costs and cost of capital overall impact
capitalized R&D costs and influence economic returns for
developing any new medicine [24,25]. An analysis from
published information on how these four drivers behave
in the specific context of rare diseases R&D models shows
that that no generic conclusion can be drawn on potential
more favorable R&D conditions for OMPs.
Success rates
Attrition rate, defined as the proportion of failures out
of the total number of projects entering any given stage
of R&D, is the most important driver of R&D cost
[24,25]. Recent research shows that reducing Phase II
and Phase III failure rates by 25% and 20% respectively
would have the greatest effect on decreasing the cost of
developing a new molecule, reducing costs by around
37% [25].
Rare diseases share specific features such as well
identified pathways for monogenic diseases or clinical
development for repurposed drugs already tested in
other indications that are likely to favor higher prob-
ability of success.
In practice however, some authors have recently docu-
mented a lower approval rate of Marketing Approval
Authorizations (MAA) for Orphan medicinal products
(59,8%) versus non-OMPs (75.6%) during the 1995–2007
period [26]. This might be explained for a large majority
of OMP programs and those in particular targeting
diseases with no available treatments, by the scarcity of
available patient pool, the heterogeneous populations
and the difficulty in identifying validated clinical end
points that are structural hurdles contributing to increased
risk of failures. This is consistent in addition with the
features of a majority of OMP clinical programs, which, by
studying treatments in patients with chronic-degenerative,
potentially fatal diseases and by favouring investigation
of drugs with novel mechanisms of action, are known
to predict an increased risk of failure [24].
Some research on Pharmaceutical R&D productivity
have revealed that success rate remains a function of
each single company or R&D organization fostering its
scientific creativity and leveraging a differentiated port-
folio strategy and R&D capabilities [24,25]. The same
variability and dynamics across companies are likely to
apply to rare diseases. Recent publications have how-
ever evidenced emergence of some potential differenti-
ated specific success drivers. First, protocol assistance
provided by EU regulation 141/2000 provides a valuable
guidance to companies developing OMPs and obtaining-
complying with such scientific advice has been recentlydocumented as a critical factor for a successful Marketing
Approval Authorization (MAA) [26]. Second, company
size, while a significant predictor of compliance with
scientific advice was also found to be an important in-
dependent predictor of outcome of a MAA [26]. This is
consistent with findings of Danzon et al. which in a
previous publication had shown that a firm’s deve-
lopment experience, measured by the number of com-
pounds with which the firm was involved as an
originator, had considerable positive effect in phase 2-
phase 3 development success showing that experience
matters for the larger and more complex phase 2 and
phase 3 trials [27]. In summary, OMP have historically
a lower MAA success rate than non orphan treatments
[26]. Success rate variability across therapeutic areas
and across companies are likely to apply to rare dis-
eases but documented productivity enhancing effects of
alliances and scientific advice regulatory incentives sug-
gest that potential differentiated factors exist for higher
success rates of Marketing Approval Authorization (MAA)
in this therapeutic space.
Development times
The average time from discovery to drug registration is
12–13 years [25]. While the number of patients typic-
ally included in clinical trials for rare diseases is smaller
than in more common diseases [22], recent research
has shown that the overall clinical development time
(Phase I to Phase III) is similar for orphan and non-
orphan programmes at about 5.7 years [28]. One possible
explanation for this may be the complexity of therapeutic
R&D in rare diseases. Small patient populations present
practical difficulties for trial recruitment. In addition, as
illustrated by contrasted outcomes across EU and USA of
recent regulatory file submission of the drugs pirfenidone,
tafamidis or mipomersen [21], regulatory requirements
across agencies remain yet to be harmonized. Combined
together, these factors can lengthen development times. In
addition, trade-offs may be occurring between time and
success rate—for example, longer Phase II development
times that allow for additional data generation before de-
ciding whether to advance to the next phase might pro-
duce higher success rates in Phase III but lengthen the
R&D process overall and may slow patient access to ther-
apies in areas where no treatment is available. In sum-
mary, development times are on average broadly similar
for orphan and non-orphan and do not appear to be more
favorable for OMPs.
Out-of-pocket costs
Some authors have conjectured that clinical development
in rare diseases should be less costly because smaller
patient populations make clinical trial out-of-pocket
costs lower than those that would be needed to
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consider that this constitutes a major driver of greater
profitability for OMPs [22,23]. In rare diseases, although
number of patients in clinical trials is smaller [23], often
the complexity of clinical trials is greater, due to factors
such as a partial or incomplete understanding of the
natural history of disease, or the large cost variability
depending on the product origin (e.g. biologic compounds
have higher out-of-pocket costs than non-biologics [24]).
Travel costs linked to difficulty of finding patients, the
often required high numbers of different clinical trial
sites or the loss of valuable experience and expertise
over the course of a trial that results from high turn-
over in CROs clinical teams and longer timelines are
additional specific cost drivers in rare diseases which
can make performing clinical trials more expensive on
a per patient basis than would be the case in more
common and better understood diseases.
Another consideration is to look at how rare diseases
companies compare to other industries and general
pharmaceutical industry in their invested out of pocket
R&D cost relative to their revenues. The pharmaceutical
industry is a competitive industry and reinvests about 16%
of its revenues in R&D, giving it the highest R&D intensity
in Europe when compared with other industries today
Figure 3.
Benchmarking Rare diseases companies described in
chapter 1 that focus on high priced first to market non
oncology drugs, these companies reinvest an even
higher share of their revenues in R&D , reinvesting 25%
of their revenues, or 1.5 times more, than the average
for the pharmaceutical sector [29]. The business model
of these companies is associated with high priced drugs to
counter balance the large focus on innovation and very
rare populations targeted. For Rare diseases companies
with such a business focus on high priced rare diseases
drugs, the high invested out of pocket R&D costs relative24.6% 
15.9% 










Figure 3 Ranking by sector of R&D investment in the EU (EFPIA **)). (to generated revenues reflect a riskier business and
strategy model.
Cost of capital
Capitalized cost is the standard accounting treatment
for long-term investments. Given the timescales and
challenges in developing a new medicine, the total cost
of a successful drug needs to account for both failures
and for the cost of capital. The cost of capital of a com-
pany measures the average cost of financing the company
(via debt or equity), and represents at an investment pro-
ject level the minimum return that needs to be generated
to break even.
The long timescales of pharmaceutical R&D mean
that the estimated R&D cost of a new drug is highly
sensitive to the cost of capital applied because R&D
costs, on average, are incurred (including for failed
projects) many years before any revenue is earned to
recover them. Recent studies show that approximately
33% to 50% of the total R&D cost of a new medicine is
due to the cost of capitalizing R&D expenditures [24,25].
Through the cost of capital, financial investors require
a risk premium for holding equity or lending money to a
particular company and its R&D portfolio. As a result,
cost of capital for small medium biotech enterprises is
often quoted higher than for larger pharmaceutical
companies and in the range of 11% to 14% in real terms
(inflation adjusted) [30]. The 11%-14% cost of capital
range is a reasonable estimate for the rare diseases
industry, where the structure is heavily composed of
small and medium size enterprises.
In summary, the financial burden of R&D expenditures
for the SMEs developing OMPs is higher on a euro-for-
euro basis than for the established large pharmaceutical
companies. Cost of capital will also vary company by
company reflecting relative riskiness of business model
and portfolio structure.% 4.4% 4.1% 3.1% 2.7% 2.1% 1.6% 0.3% 
s of R&D investment in EU 
EFPIA ) 
**) European Federation of Pharmaceutical Industries and Associations.
Rollet et al. Orphanet Journal of Rare Diseases 2013, 8:109 Page 7 of 9
http://www.ojrd.com/content/8/1/109Overall, an analysis from most recent published infor-
mation shows that factors affecting R&D investments
are not proven to be more favorable for OMPs. They
remain heavily dependent upon how, each individual
company or given R&D organization working in rare
diseases could be better in fostering its scientific cre-
ativity or leveraging a differentiated portfolio strategy
and R&D capabilities that could enhance pipeline prod-
uctivity and success.
Cost of manufacturing should determine the fair
price of OMPs?
Arguing of specific OMP legislative incentives available
in EU, a commonly encountered perception is that cost
of manufacturing should be the base to determine a fair
price of OMPs.
In real world, a balanced perspective on price setting
components of a new medicine, including rare diseases
drugs, requires a clear understanding of the dynamics
associated with R&D investments in pharmaceuticals
and on that respect, price setting constituents are no
different for rare diseases drugs than those of other
more common diseases.
To remain viable for the long term, pharmaceutical
companies must make a profit in order to be able to
continue to reinvest in the development of new me-
dicines for complex conditions. Today’s profits pay for
research and development of tomorrow’s medicines. A
major factor driving profit and price setting of any drug,
including OMP, is the unique R&D and financial invest-
ment process required to bring a product to market (see
chapter 2). Such a process comprises the constituents
that affect the financial viability of any individual R&D
investments decision in the 12–13 years timeframe
required to bring a drug from discovery to successful
registration (see chapter 2). It can therefore result into
differentiated drug prices. For example, the compara-
tively low prices of repurposed rare diseases drugs (see
chapter 1) probably reflect less demanding clinical devel-
opment requirements for this drug category as safety
profile of these drugs is often already partly studied in
other indications.
Although academic exchanges are ongoing on which
costs of R&D to integrate into investment decisions [31],
economically, a balanced drug price for any company
investing in time consuming risky pharmaceutical devel-
opment cycle, including for rare diseases, is one in which
the proposed selling price of an individual drug allows
shareholders to gain a return on their portfolio investment
that is comparable to investment returns that are available
to them in other industries or enterprises.
Price setting also includes other factors such as the
value of the treatment and its budget-impact economic-
justification to payers. Furthermore, prices are set innegotiations with purchasing parties in the context of
regulated- government established processes and a final
price is influenced by the result of the negotiations with
governments, insurers and wholesalers.
In conclusion, price setting of any pharmaceutical
product is not simply a function of its cost of manufac-
turing but multi-factorial across notably the time-value
of money and other costs impacting generation of net
cash flows over the life cycle of a drug.
Rare diseases companies are making excessive
financial returns thanks to high priced drugs?
Some authors have chosen to highlight what they see as
the excessive financial returns generated by high priced
OMPs [13], which often belong to earlier described first
to market, non oncology category. Against this perspec-
tive, it should be pointed out that if a pharmaceutical or
biotech company engaged in rare-diseases R&D is to re-
coup its R&D costs and generate profit, this investment
will also inevitably need to be recovered through lower
sales volume, given the structural limited population size
for the product.
A simple approach to simulate current R&D return is to
determine the required sales compounded annual growth
rates to achieve a pre-determined return matching at
least the cost of capital threshold, to enable break even
(ie, making neither profits nor losses). We therefore an-
alyzed 10 emblematic small medium size rare diseases
enterprises which business model is focused on high
priced first to market non oncology products described
in chapter 1.
To remain viable for the long term, any R&D spend
that pharmaceutical companies make on any given year
must be recouped (in profits resulting from resulting
sales) at a chosen fixed point in the future. Using a 10 year
time lag, assuming a 11% rate of return (risk adjusted
cost of capital) as per estimates of recent publications
[24], it follows that every 100 M $ of R&D investment
(corresponding to a net financial charge of 65 M $ for
profitable companies, assuming a 35% profit tax rate)
must produce incremental post tax profit of 185 M $
(ie 65 X 1.11^10) 10 years later. This is equivalent to
around 284 M $ pretax profit. If a trading margin on year
10 sales of 40% is assumed (excluding R&D expenditure),
it follows that 100 M $ of R&D expenditure must produce
incremental sales of 473 M $ ten years later. With a
cost of capital at 14%, it transpires that 100 M $ of
R&D spend must generate 10 years later sales of 618 M
$. Detailed calculations are described in the online
table Additional file 2.
The aggregate R&D expenditure for the universe of
10 selected rare diseases companies was 2.9 Bio $ in
2012 [29]. To generate a return of 11% to 14% on this
investment requires respective additional sales of 21
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had cumulated sales of rare diseases products of 13.6
Bio $ in 2012. Our life-cycle model suggests that to
achieve 11% to 14% return, this corresponds to 5% and
8% compound sales growth per annum for the 10 com-
panies over 10 years. This compares with current 11.8%
per annum compounded sales growth achieved over
the last 5 years for these 10 companies or, considering
structural plateau effect that follows early years of any
new product launch, a 10 year sales growth pattern
close to a 5%-10% range.
A simple simulation using the 10-year pay-back method
shows therefore that the aggregate R&D returns from rare
diseases companies are likely to be close to estimated
cost of capital of these companies. This is consistent with
comments made by Shire CEO in a recent interview re-
ferring to returns in the magnitude of 2-3% above the
cost of capital of the company [32].
Policy approaches to incentivize innovation are complex.
A valuable incentive exists for industry to invest in the
development and marketing of orphan medicinal prod-
ucts through the 10 years market exclusivity provided
by regulation (EC) No 141/2000 on orphan medicinal
products [33]. The intended effect of this regulation is
to extend the effective patent protection and to raise
expected monetary reward to rare diseases drug research
and thus encourage entry. Against some perceptions,
market exclusivity granted in regulation (EC) No 141/
2000 to an orphan medicinal product does not prevent
the marketing of other Orphan medicinal product which,
although similar to the orphan medicinal product already
authorised, would be safer, more effective or otherwise
clinically superior [31].
Current context of economic constraints in Europe
however justifies the need to pay close attention to the
rationale of maintaining such incentive in the context
of potential return on investments of companies offering
high priced drugs. Simulation of potential financial returns
of small medium sized companies focusing on high priced
rare diseases treatments shows that their returns are likely
to be close to their cost of capital. When linking financial
returns to drug prices, it also infers that the price charged
for rare diseases treatments targeting very rare disorders
must be seen in context of the rarity of the condition,
the number of patients treated, and the R&D financial
investment incurred. Whether the prices are justified
in regard to the medical/social value of the OMPs is a
different but critical matter not debated in this analysis.
Outlook and conclusion
Misconceptions abound regarding the pricing of rare
diseases drugs and reflect a poor appreciation of the
R&D model and the affordability and value of OMPs. It
is critical that multiple stakeholders understand andaddress these misconceptions in order to safeguard the
overarching values of universality, equity, solidarity that
are necessary to maintain equitable access to treatments
for rare diseases.
Rare diseases remain unchartered territory and pose
challenges for drug developers and to policy makers
alike. Drug development in this arena focuses in the
majority of programs on exploring new treatment targets
using innovative technologies. Small size population
makes research in rare diseases a challenging endeavor.
To ensure the successful continuation of dynamic
OMPs R&D within rare-diseases public health policy,
policy makers must reward innovation based upon unmet
need and patient outcome. Policies that inflate research
costs or protract the time from discovery to market in-
crease the size of investments required for R&D.
At company level, technology platforms, diseases fran-
chises, global reach are potential levers to sustain pro-
fitable development of OMPs. Simulation of potential
financial returns of small medium sized rare diseases
companies focusing on high priced drugs show that their
economic returns are likely to be close to their cost of
capital. Although heavily dependent upon R&D capabil-
ities of each individual company or R&D organization,
continuous flow of R&D financial investment should
allow industry to increasingly include efficiencies in
research and development in cost considerations to its
customers.
Industry should also encourage development of a spe-
cific OMP value based approach embedded into a specific
policy framework. Although an important component,
it is not sustainable for the industry to continue only
justifying value and prices of rare diseases treatments
on the sole basis of the rarity of a condition. A consistent
value definition that could mirror the significant benefit
criterion would offer a possible construct for more
comprehensive guidance to pricing and reimbursement
decision-making, while helping to send appropriate sig-
nals as to priorities for future investment in R&D.
A broader understanding by clinicians, the public, and
policy makers of the complexity of clinical programs re-
quired to deliver OMPs to market is required for stake-
holders to better comprehend the decisions required
and made by industry. There is no silver bullet. The an-
swer to achieving improved sustainable patient access to
new and innovative therapies requires solid rare-diseases
public health policy founded on early dialogue, under-
standing and education.Additional files
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